MedPath

Effects of Faba Bean Fractions as Ingredients in Novel Food Products on Glycemia, Appetite and Metabolic Control

Not Applicable
Active, not recruiting
Conditions
Diabetes
Obesity
Interventions
Dietary Supplement: Crackers/pasta with added faba bean protein concentrate
Dietary Supplement: Crackers/pasta with added faba bean flour
Dietary Supplement: Crackers/pasta with no faba bean fraction
Dietary Supplement: Crackers/pasta with added faba bean protein isolate
Dietary Supplement: Crackers/pasta with added faba bean starch
Registration Number
NCT02658591
Lead Sponsor
University of Toronto
Brief Summary

The investigators hypothesized that consuming crackers or pasta enriched with faba bean fractions (faba bean protein concentrate, faba bean protein isolate, faba bean flour and faba bean starch), would reduce the blood glucose response to the meal compared to foods without faba bean components and reduce food intake at a meal

Detailed Description

Not available

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
Male
Target Recruitment
60
Inclusion Criteria
  • Non-smoking
  • No metabolic disease
  • BMI 20 - 25 kg/m^2
  • Male
  • Age 18-30
Exclusion Criteria
  • Intolerance to treatments
  • Currently taking appetite-modifying medications
  • Restrictive eating
  • Smoking
  • Over- or underweight
  • Breakfast-skipping

Study & Design

Study Type
INTERVENTIONAL
Study Design
CROSSOVER
Arm && Interventions
GroupInterventionDescription
Faba bean protein concentrateCrackers/pasta with added faba bean protein concentrateCrackers/pasta with added faba bean protein concentrate
Faba bean flourCrackers/pasta with added faba bean flourCrackers/pasta with added faba bean flour
ControlCrackers/pasta with no faba bean fractionCrackers/pasta with no faba bean fraction
Faba bean protein isolateCrackers/pasta with added faba bean protein isolateCrackers/pasta with added faba bean protein isolate
Faba bean starchCrackers/pasta with added faba bean starchCrackers/pasta with added faba bean starch
Primary Outcome Measures
NameTimeMethod
Change in blood glucose levelsStarting at the beginning of each session (0 minutes, before consumption of treatment) and every 15 - 30 minutes up to 200 minutes (time of completion of each session)

Each participant will attend 5 sessions in total (randomized 5-arm cross-over design)

Change in gut hormone levels measured in the bloodStarting at the beginning of each session (0 minutes, before consumption of treatment) and every 30 minutes up to 200 minutes (time of completion of each session)

Each participant will attend 5 sessions in total (randomized 5-arm cross-over design)

Secondary Outcome Measures
NameTimeMethod
Subjective appetiteFrom 0 to 200 minutes

Measured using Visual Analog Scales (VAS)

Ad libitum food (pizza meal) intake as measured by the amount of pizza (in grams) consumed during the 20 minute period120 minutes after completion of treatment, 20 minutes were allocated to allow for pizza consumption

Each participant will also answer questions related to physical comfort, motivation to eat, and rating feelings of energy and fatigue using Visual Analog Scales (VAS)

Trial Locations

Locations (1)

University of Toronto

🇨🇦

Toronto, Ontario, Canada

© Copyright 2025. All Rights Reserved by MedPath